Report Description of the APAC Anti-Fungal Drugs Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for APAC Anti-Fungal Drugs Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the APAC Anti-Fungal Drugs Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

APAC Anti-Fungal Drugs Market Analysis Executive Summary

Anti-fungal drugs are used to cure fungal infections which are usually caused by the unclean, unhygienic and damp environments. Fungal infections are the invasion of epithelial tissue by microscopic organisms. Systemic fungal infections are caused by indigestion or inhalation of fungus spores and cause fungal pneumonia and opportunistic fungus causes diseases like candidiasis, meningitis, mucormycosis, etc. Most of the fungal infections and fungal diseases are generally non-lethal but they are very uncomfortable to live with. Commonly occurring fungal infections are responsible for the rise of the antifungal drugs market. Antifungal drugs work through various mechanisms such as inhibiting cell wall formation, cell membrane disruption, and cell division

Market Size and Key Findings

The APAC Anti-Fungal Drugs Market Analysis size stood at around USD 2.18 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 4.1% during the forecast period.

The size of the Antifungal Drugs Market in the Asia Pacific has been estimated at USD 2.18 billion in 2021. This value is further forecasted to be growing at a CAGR of 4.1%.



Market Dynamics

Market Growth Drivers Analysis

Fungal infections are regarded as a major public health issue all over the Asia Pacific. The Change in environmental conditions and an increase in the spread of various infectious diseases from person to person are driving the APAC Antifungal drugs market. Also, the growing number of contagious fungal infections such as pythiosis and mucormycosis are propelling the growth of the Asia-Pacific antifungal drugs market. In addition, the Adoption of advanced technologies in the production of various pharmaceuticals and processes for various infectious diseases around the region is expected to boost the market growth.

Market Restraints

Long-term usage of these treatments has increased adverse effects, which has posed a challenge to market expansion. In addition, variations in the rate of medicine production are also slowing the market demand for antifungal drugs. The market's growth rate is further hampered by a scarcity of competent workers in the medication manufacturing industry. The government's stringent regulations and procedures for approving new pharmaceuticals further limit market demand, in addition, the rising occurrences of cancer, an increase in hematopoietic stem cell transplantation, and other causes that weaken the immune system are fueling the expansion of the APAC antifungal drugs market.

Competitive Landscape

Key Players

The key companies of the antifungal drugs market mentioned in the report are Vertex Pharmaceuticals, Abbott Laboratories, Bayer Healthcare, Baxter, Johnson & Johnson, Astellas Pharma Inc, Novartis, GlaxoSmithKline, Arbor Pharmaceuticals Inc, Pfizer, Kramer Laboratories, Sanofi-Aventis, Teva Pharmaceuticals, and Gilead.

Products in Pipeline

• The Als candidal vaccine candidate has been licensed to NovaDigm Therapeutics. Currently, development is focused on using the recombinant N terminus of Als3p (rAls3p-N), formulated in alum as an adjuvant. The rAls3p-N vaccine is entering good manufacturing practice (GMP) evaluation, with subsequent preclinical toxicity studies planned. A Phase I clinical trial protocol has been developed and presented to the FDA in a pre-IND meeting in preparation for future clinical studies, which are predicted to begin within the next year.


• The pan-fungal laminarin-CRM 197 vaccine, has been licensed to Novartis, with a GMP formulation of this vaccine ready to start clinical development (A. Cassone, personal communication).

Notable Recent Deals

1. Hoffmann-La Roche Ltd (Roche or the company) develops and commercializes innovative therapeutic and diagnostic products. The company undertakes research, along with manufacturing products in several therapeutic areas like neuroscience, ophthalmology, immunology, oncology, and immunology. The company has operations in North America, Asia, Africa, Oceania, Australia, Europe, and Latin America, and is headquartered in Basel, Switzerland.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The Pharmaceutical Affairs Law of Japan requires a license for marketing authorization when importing and selling pharmaceutical products manufactured in other countries. The license may be revoked if the quality management methods and post marketing safety management methods applied with respect to the pharmaceutical product fail to conform to the standards stipulated in the ordinances promulgated by the Ministry of Health, Labour and Welfare.

Private plans typically include medical and pharmacy benefits. Drugs used with Durable Medical Equipment (DME) are often covered under the pharmacy benefit. Physician-administered drugs, regardless of formulation, are typically covered and paid under the medical benefit. FDA approval is typically a prerequisite for coverage, but private plans have a greater flexibility than public plans in defining the benefit category and placement of drugs on formularies, as well as adopting utilization controls.